Preclinical evaluation of near-infrared (NIR) fluorescently labeled Cetuximab as a potential tool for fluorescence-guided surgery

Abstract

The high rate of recurrence in patients with pancreatic ductal adenocarcinoma (PDAC) could be reduced by supporting the surgeons in discriminating healthy from diseased tissues with intraoperative fluorescence-guidance. Here, we studied the suitability of Cetuximab, a therapeutic monoclonal antibody targeting the human epidermal growth factor receptor (EGFR), NIR fluorescently labeled as a new tool for fluorescence-guided surgery (FGS). Distribution and binding of systemically injected Cetuximab Alexa Fluor 647 conjugate (Cetux-Alexa-647) and the co-injected control human IgG Alexa Fluor 750 conjugate (hIgG-Alexa-750) was studied over 48h by near-infrared fluorescence (NIRF) imaging in mice bearing human orthotopic AsPC-1 and MIA PaCa-2 PDAC tumors. Cetux-Alexa-647, but not the control hIgG-Alexa-750 fluorescence, was specifically detected in vivo in both primary pancreatic tumors and in metastases of AsPC-1 tumors as small as 1 mm, with maximum fluorescence intensities at 24 h. Lifetime (LT) analysis and NIRF microscopy of tumor sections confirmed the binding specificity of Cetux-Alexa-647 to PDAC cells. Comparable results were obtained with Cetuximab conjugated to Alexa Fluor 750 dye (Cetux-Alexa-750). Fluorescence-guided dissection, performed 24 h after injection of Cetuximab conjugated to IRDye 800CW (Cetux-800CW), enabled a real time delineation of AsPC-1 tumor margins, and small metastases. Odyssey scans revealed that only the vital part of the tumor, but not the necrotic part was stained with Cetux-800CW. NIR fluorescently labeled Cetuximab may be a promising tool that can be applied for FGS to visualize tumor margins and metastatic sites in order to allow a precise surgical resection. This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/29PJ0Hx
via IFTTT